Dayna Osborne
Primary Care · Janesville, WINPI 1437662574
Payments from drug & device makers
What this record shows
This record is dominated by education: $874 of the $1,418 with a category attached, or 61.6%. 12 manufacturers reported payments, led by Johnson & Johnson at 24.6% of the total. Reporting peaked in 2022 at $525 and has fallen 52.5% since, to $249 in 2025.
Across 19 payments — averaging $74.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$349
- E.r. Squibb & Sons, L.L.C.$243
- Sanofi-aventis U.S. LLC$186
- Genentech USA, Inc.$127
- Incyte Corporation$100
- Astellas Pharma US Inc$99
- plus $315 from 6 others
What the payments were for
- Food & beverage$54438%
- Education$87462%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 5 | $349 |
| E.r. Squibb & Sons, L.L.C. | 2 | $243 |
| Sanofi-aventis U.S. LLC | 2 | $186 |
| Genentech USA, Inc. | 1 | $127 |
| Incyte Corporation | 1 | $100 |
| Astellas Pharma US Inc | 1 | $99 |
| Boston Scientific | 1 | $92 |
| Seagen Inc. | 1 | $91 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $65 |
| Novartis | 2 | $30 |
| Taiho Oncology, Inc. | 1 | $22 |
| AstraZeneca | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,418 in reported general payments places this provider in the 80th percentile of 52 primary care providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 13 | $250,095 |
| Abiraterone Acetate | 16 | $43,933 |
| Gabapentin | 13 | $484 |
| Acyclovir | 14 | $312 |
| Anastrozole | 11 | $306 |
| Nystatin | 11 | $248 |
| Famotidine | 26 | $236 |
| Omeprazole | 14 | $221 |
| Oxycodone Hcl | 12 | $179 |
| Prednisone | 28 | $160 |
| Levothyroxine Sodium | 20 | $154 |
Paid to pharmacies, not to this prescriber.
Other primary care in Janesville
- Mollie JesbergerJanesville$92
- Michael PotnekMilwaukee$71K
- Jennifer KrallWausau$4K
- Stephanie BrownKenosha$3K
- Emily OrganBrookfield$2K
- Heather MeeusenPlymouth$2K
- Kelly StoneMilwaukee$2K
- Courtney LammMilwaukee$2K
- Mary WiseMilwaukee$2K
- Jennifer ErichPleasant Prairie$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.